Results 11 to 20 of about 4,608 (197)

Recent Therapeutic Advances in Pituitary Carcinoma [PDF]

Journal of Immunotherapy and Precision Oncology, 2023
Pituitary carcinoma (PC) is a rare, aggressive malignancy that comprises 0.1–0.2% of all pituitary tumors. PC is defined anatomically as a pituitary tumor that metastasizes outside the primary intrasellar location as noncontiguous lesions in the central ...
Ian J. Robertson, Timothy A. Gregory, Steven G. Waguespack, Marta Penas-Prado, Nazanin K. Majd   +4 more
doaj   +1 more source

Prognostic implications of [¹⁸F]FDG PET and metabolic changes in patients with advanced metastatic neuroendocrine tumors undergoing rechallenge PRRT: final results from a multicenter 10-year survival WARMTH study. [PDF]

Theranostics
Santo G, Rodrigues M, Paez D, Morozova O, Kabasakal L, Kairemo K, Grana CM, Baum RP, di Santo G, Virgolini IJ.   +9 more
europepmc   +3 more sources

Perspective of molecular imaging and peptide receptor radionuclide therapy in pancreatic neuroendocrine tumors: where do we stand?

Journal of Pancreatology, 2023
The clinical use of nuclear medicine imaging and therapy in pancreatic neuroendocrine tumors has been greatly strengthened since the approval of 68Ga-DOTATATE and 177Lu-DOTATATE. However, many aspects are still under discussion.
Wenjia Zhu, Meixi Liu, Li Huo
doaj   +1 more source

PRRT: identikit of the perfect patient [PDF]

Reviews in Endocrine and Metabolic Disorders, 2020
AbstractPeptide receptor radionuclide therapy (PRRT) has been strengthened since the publication of NETTER-1. Nevertheless, the correct positioning in the therapeutic algorithm is debated, and no optimal sequence has yet been standardized. Possible criteria to predict the response to PRRT in neuroendocrine tumors (NET) have been proposed.
Albertelli M., Dotto A., Di Dato C., Malandrino P., Modica R., Versari A., Colao A., Ferone D., Faggiano A.   +8 more
openaire   +3 more sources

Pituitary function following peptide receptor radionuclide therapy for neuroendocrine tumours

Cancer Medicine, 2021
Peptide receptor radionuclide therapy (PRRT) is an increasingly used treatment for unresectable neuroendocrine tumours (NETs) that express somatostatin receptors.
Marianne S. Elston, Amanda Love, Dev Kevat, Richard Carroll, Zhen Rong Siow, Sharon Pattison, Veronica Boyle, Eva Segelov, Andrew H. Strickland, David Wyld, Richard Gauci, Kim Kennedy, David Ransom, the Commonwealth Neuroendocrine Tumour Collaboration (CommNETs)   +13 more
doaj   +1 more source

The Safety and Efficacy of the Repeated PRRT with [90Y]Y/[177Lu]Lu-DOTATATE in Patients with NET

International Journal of Endocrinology, 2021
Purpose. The peptide receptor radionuclide therapy (PRRT) is a treatment option for patients with disseminated, inoperable G1 and G2 neuroendocrine tumours (NETs).
Anna Zemczak, Paweł Gut, Dariusz Pawlak, Maciej Kołodziej, Leszek Królicki, Beata Kos-Kudła, Marek Ruchała, Grzegorz Kamiński, Jolanta Kunikowska   +8 more
doaj   +1 more source

New Insights in PRRT: Lessons From 2021

Frontiers in Endocrinology, 2022
Peptide receptor radionuclide therapy (PRRT) using radiolabeled somatostatin analogs has been used for over two decades for the treatment of well-differentiated neuroendocrine tumors (NETs), and the publication of the NETTER-1 trials has further strengthened its clinical use. However, many aspects of this treatment are still under discussion.
Giulia Puliani, Giulia Puliani, Alfonsina Chiefari, Marilda Mormando, Marta Bianchini, Rosa Lauretta, Marialuisa Appetecchia   +6 more
openaire   +3 more sources

Initial clinical evaluation of indigenous 90Y-DOTATATE in sequential duo-PRRT approach (177Lu-DOTATATE and 90Y-DOTATATE) in neuroendocrine tumors with large bulky disease: Observation on tolerability,90Y-DOTATATE post- PRRT imaging characteristics (bremsstrahlung and PETCT) and early adverse effects

World Journal of Nuclear Medicine, 2021
177Lu-DOTATATE peptide receptor radionuclide therapy (PRRT) alone has lesser potential in the clinical setting of neuroendocrine tumor (NET) with large bulky disease and nonhomogeneous somatostatin receptors (SSTR) distribution, owing to lower energy ...
Rahul Parghane, Arpit Mitra, Trupti Bannore, Sutapa Rakshit, Sharmila Banerjee, Sandip Basu   +5 more
doaj   +1 more source

Neoadjuvant PRRT for advanced pNEN: an unusual highlander [PDF]

Endocrine, 2021
A case of pancreatic neuroendocrine neoplasm treated with neoadjuvant PRRT before sugery, obtaining complete tumor resection.
Zanata, Isabella, Ambrosio, Maria Rosaria, Zatelli, Maria Chiara   +2 more
openaire   +3 more sources

The Challenge of Evaluating Response to Peptide Receptor Radionuclide Therapy in Gastroenteropancreatic Neuroendocrine Tumors: The Present and the Future

Diagnostics, 2020
The NETTER-1 study has proven peptide receptor radionuclide therapy (PRRT) to be one of the most effective therapeutic options for metastatic neuroendocrine tumors (NETs), improving progression-free survival and overall survival.
Virginia Liberini, Martin W. Huellner, Serena Grimaldi, Monica Finessi, Philippe Thuillier, Alfredo Muni, Riccardo E. Pellerito, Mauro G. Papotti, Alessandro Piovesan, Emanuela Arvat, Désirée Deandreis   +10 more
doaj   +1 more source